Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07413666 · ClinicalTrials.gov registry record · Phase 1
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
A Phase 1 study of Healthy Adult Male and Female Volunteers, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
- 1
- Study location
NCT07413666: Recruiting Phase 1 study of Healthy Adult Male and Female Volunteers, sponsored by Centessa Pharmaceuticals (UK) Limited.
NCT07413666 is a Phase 1 study of Healthy Adult Male and Female Volunteers that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 212 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07413666, a Phase 1 study of Healthy Adult Male and Female Volunteers, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
- 1
- Study location
Study Summary
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Primary Outcome
Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single ascending doses of ORX489 in healthy adult participants.
Conditions Studied
Interventions
- DRUG ORX489 Tablets
- OTHER Placebo Tablets
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT07413666 shows while recruiting
NCT07413666 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher).
The record links to 1 condition, with Healthy Adult Male and Female Volunteers appearing as the primary indexed condition, and to 2 interventions - of which ORX489 Tablets is the first listed.
NCT07413666 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT07413666 about?
NCT07413666 is a clinical study titled "A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years". Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
What is the current status of trial NCT07413666?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2026-02-25. Estimated completion is 2027-06-30.
What conditions does trial NCT07413666 study?
This clinical trial studies the following conditions: Healthy Adult Male and Female Volunteers.
What interventions are being tested in trial NCT07413666?
The interventions under investigation include: ORX489 Tablets (DRUG), Placebo Tablets (OTHER).
Who is sponsoring clinical trial NCT07413666?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07413666 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Male and Female Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07413666's enrollment target sits among peer trials
212 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI